Sanofi to acquire Kymab for $1.1bn
pharmafile | January 11, 2021 | News story | Sales and Marketing | Malin, Sanofi, kymab
Sanofi is to acquire clinical-stage biopharmaceutical company Kymab for approximately $1.1 billion.
In addition to this upfront sum, Paris-headquartered Sanofi is also expected to pay up to $350 million upon achievement of certain milestones.
The transaction will result in Sanofi having full global rights to KY1005, a fully human monoclonal antibody that has a novel mechanism of action. KY1005 binds to OX40-Ligand and has the potential to treat a wide variety of immune-mediated diseases and inflammatory disorders.
The closing of the transaction, which is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions, is expected in the first half of this year.
Paul Hudson, Sanofi’s Chief Executive Officer, said: “The Kymab acquisition adds KY1005 to our dynamic pipeline, a potential first-in-class treatment for a range of immune and inflammatory diseases. The novel mechanism of action may provide treatment for patients with suboptimal responses to available therapies.
“We understand from our ongoing work in debilitating immunological diseases how critical it is to find the right treatment for each patient. We look forward to rapidly developing this investigational medicine.”
Simon Sturge, Chief Executive Officer at Kymab, added: “The agreement is a testament to the commitment, drive and expertise of the entire Kymab team and we are pleased to receive this endorsement from Sanofi.
“With its significant global resources, we believe Sanofi is the perfect partner to progress Kymab’s pipeline of products and the merger will expedite the time it takes for our novel therapies to get to patients.”
Darcy Jimenez
Related Content
Sanofi shares phase 3 trial results for Sarclisa in multiple myeloma treatment
Sanofi has announced data from the IMROZ phase 3 trial which assessed Sarclisa (isatuximab) in …
Sanofi, Formation Bio and OpenAI enter AI collaboration
Sanofi, Formation Bio and OpenAI have announced that they have entered into a collaboration with …
Fulcrum Therapeutics and Sanofi enter collaboration for facioscapulohumeral muscular dystrophy treatment
Fulcrum Therapeutics has announced that it has entered into a collaboration and license agreement with …
